Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment

Toshio Kubo, Nagio Takigawa, Katsuyuki Kiura, Ayumi Nishida, Nobuaki Ochi, Hiromi Kashihara, Shigeki Umemura, Akiko Hisamoto, Mitsune Tanimoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A 51-year-old female presented with left facial palsy. She had adenocarcinoma of the lung with multiple brain metastases. The primary tumor regressed after treatment with gefitinib, however, neurological symptoms progressed rapidly because of meningeal carcinomatosis, when a deletion mutation in exon 19 of the epidermal growth factor receptor in cells from her cerebrospinal fluid was detected. After performing lumbo-peritoneal shunting, her symptoms improved dramatically and she had been well without peritoneal dissemination for 15 months, continuing gefitinib treatment. Finally, she died 18 months after lumbo-peritoneal shunting. A T790M acquired-resistance mutation in exon 20 of the epidermal growth factor receptor was found from her mesenteric lymph nodes and cerebrospinal fluid at autopsy. A lumbo-peritoneal shunt might be considered for meningeal carcinomatosis refractory to gefitinib treatment without an emergence of a T790M mutation.

Original languageEnglish
Pages (from-to)2759-2760
Number of pages2
JournalAnticancer research
Volume29
Issue number7
Publication statusPublished - Jul 2009

Keywords

  • Epidermal growth factor receptor
  • Gefitinib
  • Lumbo-peritoneal shunt
  • Lung cancer
  • Meningeal carcinomatosis
  • T790M

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment'. Together they form a unique fingerprint.

  • Cite this

    Kubo, T., Takigawa, N., Kiura, K., Nishida, A., Ochi, N., Kashihara, H., Umemura, S., Hisamoto, A., & Tanimoto, M. (2009). Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment. Anticancer research, 29(7), 2759-2760.